Form 4: Tandem Diabetes Care EVP Mark Novara Reports Stock Transactions

Mark Novara, EVP & Chief Commercial Officer of Tandem Diabetes Care, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• On March 17, 2025, Mark Novara, EVP & Chief Commercial Officer of Tandem Diabetes Care, reported transactions involving the company's stock.
• Novara acquired 7,415 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.
• Simultaneously, 2,739 shares were withheld by Tandem Diabetes Care to satisfy tax withholding requirements at a price of $19.17.
• Following these transactions, Novara directly owns 24,134 shares of Tandem Diabetes Care common stock and 51,902 restricted stock units.
• The RSUs were awarded on December 15, 2023, under the company's 2023 Long-Term Incentive Plan and vest over time.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Positives

• The vesting of RSUs indicates that Novara is meeting the conditions of the 2023 Long-Term Incentive Plan.

Industry Context

Executive stock transactions are a normal part of corporate governance and compensation practices. Form 4 filings provide transparency into these transactions, allowing investors to track insider activity.

Stakeholder Impact

• Shareholders can monitor insider transactions for insights into management's perspective on the company's performance.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, Mark Novara, restricted stock units, RSU, Form 4, insider trading, stock transaction, executive compensation